Virus Res. 2013 Jul 22. doi:pii: S0168-1702(13)00231-1. 10.1016/j.virusres.2013.07.009.
Recent Posts
- EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services   Â
- Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
- EpiVax Enters its Next Chapter with SV Health Investors
- Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
- Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
Recent Comments
No comments to show.